CN105987945A - Quantitative method for occupancy of N-bond sialylated sugar chains on glycoprotein and application of quantitative method in hepatoma marker screening - Google Patents
Quantitative method for occupancy of N-bond sialylated sugar chains on glycoprotein and application of quantitative method in hepatoma marker screening Download PDFInfo
- Publication number
- CN105987945A CN105987945A CN201510060851.XA CN201510060851A CN105987945A CN 105987945 A CN105987945 A CN 105987945A CN 201510060851 A CN201510060851 A CN 201510060851A CN 105987945 A CN105987945 A CN 105987945A
- Authority
- CN
- China
- Prior art keywords
- glycoprotein
- sialylated sugar
- solution
- hco
- occupancy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 60
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 60
- 238000012216 screening Methods 0.000 title claims abstract description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 title description 8
- 238000004445 quantitative analysis Methods 0.000 title description 4
- 239000003550 marker Substances 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 40
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims abstract description 34
- 239000004005 microsphere Substances 0.000 claims abstract description 26
- 108010015899 Glycopeptides Proteins 0.000 claims abstract description 22
- 102000002068 Glycopeptides Human genes 0.000 claims abstract description 22
- 230000003647 oxidation Effects 0.000 claims abstract description 19
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 230000013595 glycosylation Effects 0.000 claims abstract description 12
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 11
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 claims abstract description 8
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 claims abstract description 8
- 239000012472 biological sample Substances 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 7
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims abstract description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 25
- 239000007853 buffer solution Substances 0.000 claims description 17
- 238000002372 labelling Methods 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 10
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 8
- 239000004202 carbamide Substances 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 238000000074 matrix-assisted laser desorption--ionisation tandem time-of-flight detection Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- 235000013877 carbamide Nutrition 0.000 claims 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 229910020889 NaBH3 Inorganic materials 0.000 claims 2
- 230000009514 concussion Effects 0.000 claims 2
- 238000010612 desalination reaction Methods 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- WSFSSNUMVMOOMR-DICFDUPASA-N dideuteriomethanone Chemical compound [2H]C([2H])=O WSFSSNUMVMOOMR-DICFDUPASA-N 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 102000035118 modified proteins Human genes 0.000 claims 1
- 108091005573 modified proteins Proteins 0.000 claims 1
- 108040002068 peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activity proteins Proteins 0.000 claims 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims 1
- 238000012797 qualification Methods 0.000 claims 1
- 238000004064 recycling Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 235000009518 sodium iodide Nutrition 0.000 claims 1
- 238000010183 spectrum analysis Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 abstract description 12
- 208000014018 liver neoplasm Diseases 0.000 abstract description 12
- 238000004949 mass spectrometry Methods 0.000 abstract description 6
- 239000000090 biomarker Substances 0.000 abstract description 3
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 238000000575 proteomic method Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 9
- 210000005228 liver tissue Anatomy 0.000 description 8
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000004988 N-glycosylation Effects 0.000 description 5
- 238000011033 desalting Methods 0.000 description 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 5
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 3
- 102000035122 glycosylated proteins Human genes 0.000 description 3
- 108091005608 glycosylated proteins Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000009450 sialylation Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102100023123 Mucin-16 Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000001196 time-of-flight mass spectrum Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- -1 DTT) Chemical compound 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002446 heavy isotope labeling Methods 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- NCGWKCHAJOUDHQ-UHFFFAOYSA-N n,n-diethylethanamine;formic acid Chemical compound OC=O.OC=O.CCN(CC)CC NCGWKCHAJOUDHQ-UHFFFAOYSA-N 0.000 description 1
- 238000001186 nanoelectrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010844 nanoflow liquid chromatography Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及一种定量糖蛋白上N-连唾液酸化糖链占有率的方法及其在肝癌标志物筛选中的应用。首先取同一种状态下含糖蛋白的生物样品等量两份,然后用高碘酸钠溶液对其分别处理以进行差异氧化,之后利用蛋白层次上的酰肼化学法富集差异氧化后的样品中的糖蛋白,然后利用不同稳定同位素差异标记酰肼微球上的糖肽,再然后用肽糖苷酶PNGase F处理,最后对混合差异标记的N-糖肽进行质谱分析,以定量N-连唾液酸化糖链的占有率。本方法可以用于糖基化修饰的蛋白质组学分析,能同时获取相应的糖蛋白、糖肽和糖基化位点的鉴定结果,尤其可用于人肝癌(HCC)的潜在生物标志物的筛选。本方法简便,高效。The invention relates to a method for quantifying the occupancy of N-linked sialylated sugar chains on glycoproteins and its application in screening liver cancer markers. First, take two equal biological samples containing glycoproteins in the same state, and then treat them separately with sodium periodate solution for differential oxidation, and then use the hydrazide chemical method on the protein level to enrich the differentially oxidized samples Then use different stable isotopes to differentially label the glycopeptides on the hydrazide microspheres, then treat them with the peptide glycosidase PNGase F, and finally perform mass spectrometry analysis on the mixed differentially labeled N-glycopeptides to quantify N-linked Occupancy of sialylated sugar chains. This method can be used for proteomic analysis of glycosylation modification, and can simultaneously obtain the identification results of corresponding glycoproteins, glycopeptides and glycosylation sites, especially for the screening of potential biomarkers of human liver cancer (HCC) . This method is simple and efficient.
Description
技术领域 technical field
本发明属于蛋白质组学研究方向糖基化蛋白质组学技术领域,具体涉及基于酰肼化学的差异氧化和标记法高通量定量糖蛋白上N-连唾液酸化糖链占有率的方法及其在肝癌标志物筛选中的应用。 The invention belongs to the technical field of glycosylation proteomics in the direction of proteomics research, and specifically relates to a method for high-throughput quantification of the occupancy of N-linked sialylated sugar chains on glycoproteins by differential oxidation and labeling based on hydrazide chemistry and its application in Application in the screening of liver cancer markers.
背景技术 Background technique
蛋白质糖基化作为一种最普遍且最重要的翻译后修饰,在蛋白质折叠、构象稳定和活性等方面起着重要的作用。糖基化蛋白质(简称糖蛋白)参与了细胞与细胞、细胞与细胞外基质的分子识别、细胞凋亡、蛋白质相互作用、免疫应答等生命过程。因此,糖蛋白的异常变化往往伴随着许多疾病的发生和发展。也就是说,某一疾病中异常的糖蛋白可以作为该疾病的标志物。目前,临床上所用的疾病标志物大多是糖基化蛋白质,如甲胎蛋白(AFP)是肝癌的标志蛋白,癌症抗原125(cancer antigen 125)是恶性肿瘤的标志物,以及前列腺癌的特异抗原等等。因此,对于糖蛋白的深入研究具有非常重要的意义。 Protein glycosylation, as one of the most common and important post-translational modifications, plays an important role in protein folding, conformational stability and activity. Glycosylated proteins (glycoproteins for short) are involved in the molecular recognition of cells and cells, cells and extracellular matrix, apoptosis, protein interaction, immune response and other life processes. Therefore, abnormal changes in glycoproteins are often accompanied by the occurrence and development of many diseases. That is, abnormal glycoproteins in a certain disease can be used as markers of the disease. At present, most of the disease markers used clinically are glycosylated proteins, such as alpha-fetoprotein (AFP) is a marker protein of liver cancer, cancer antigen 125 (cancer antigen 125) is a marker of malignant tumors, and the specific antigen of prostate cancer etc. Therefore, in-depth research on glycoproteins is of great significance.
糖蛋白上N-连唾液酸化糖链是一种常见且非常重要的聚糖,唾液酸位于糖链的末端。在细胞中,唾液酸化糖链有着诸多重要的生物学功能,包括细胞分子间相互作用,细胞特征的形成,以及细胞代谢等等。对于这类糖基化蛋白的研究表明,糖蛋白的唾液酸化的异常与很多癌症如乳腺癌,结肠癌,白血病,胰腺癌等密切相关,因此,蛋白质组学专家们对于这类糖蛋白的关注度越来越高。目前已有多种糖蛋白质组学的方法用于唾液酸化糖蛋白的定性和定量,包括特异的凝集素方法(文献1.Kubota,K.et al.Analysis of glycopeptides using lectin affinity chromatography with MALDI-TOF mass spectrometry.Analytical chemistry 80,3693-3698,doi:10.1021/ac800070d(2008).),二氧化钛(文献2.Larsen,M.R.,Jensen,S.S.,Jakobsen,L.A.&Heegaard,N.H.Exploring the sialiome using titanium dioxide chromatography and mass spectrometry.Mol.Cell.Proteomics 6,1778-1787,doi:10.1074/mcp.M700086-MCP200(2007).)和钛(Ⅳ)金属离子亲和色谱法(文献3.Zhu,J.et al.A simple integrated system for rapid analysis of sialic-acid-containing N-glycopeptides from human serum.Proteomics 13,1306-1313,doi:10.1002/pmic.201200367(2013).),以及改进的酰肼化学方法(文献4.Zeng,Y.,Ramya,T.N.,Dirksen,A.,Dawson,P.E.&Paulson,J.C.High-efficiency labeling of sialylated glycoproteins on living cells.Nature methods 6,207-209,doi:10.1038/nmeth.1305(2009).文献5.Nilsson,J.et al.Enrichment of glycopeptides for glycan structure and attachment site identification.Nature methods 6,809-811,doi:10.1038/nmeth.1392(2009).文献6.Tian,Y.,Esteva,F.J.,Song,J.&Zhang,H.Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry.Mol.Cell.Proteomics,doi:10.1074/mcp.M111.011403(2012).)。改进的酰肼化学方法是指用低浓度的高碘酸钠溶液在低温下和短时间内去选择性氧化唾液酸化的糖蛋白或糖肽,从而实现对其富集和分析。这些已报道的方法直接比较了疾病样品和正常样品间同一个糖基化位点上唾液酸化的不同,而对于同一种状态的样品中的糖蛋白上的唾液酸化糖链的占有率没有研究。 The N-linked sialylated sugar chain on glycoprotein is a common and very important glycan, and sialic acid is located at the end of the sugar chain. In cells, sialylated sugar chains have many important biological functions, including the interaction between cell molecules, the formation of cell characteristics, and cell metabolism. Studies on this type of glycosylated protein have shown that abnormal sialylation of glycoprotein is closely related to many cancers such as breast cancer, colon cancer, leukemia, pancreatic cancer, etc. Therefore, proteomics experts pay attention to this type of glycoprotein The degree is getting higher and higher. At present, a variety of glycoproteomics methods have been used to identify and quantify sialylated glycoproteins, including specific lectin methods (document 1. Kubota, K. et al. Analysis of glycopeptides using lectin affinity chromatography with MALDI-TOF mass spectrometry.Analytical chemistry 80,3693-3698, doi:10.1021/ac800070d(2008).), titanium dioxide (document 2.Larsen,M.R.,Jensen,S.S.,Jakobsen,L.A.&Heegaard,N.H.Exploring the sialiome using titanium dioxide massa spectrometry.Mol.Cell.Proteomics 6,1778-1787, doi:10.1074/mcp.M700086-MCP200(2007).) and titanium (Ⅳ) metal ion affinity chromatography (document 3.Zhu, J.et al.A simple integrated system for rapid analysis of sialic-acid-containing N-glycopeptides from human serum.Proteomics 13,1306-1313,doi:10.1002/pmic.201200367(2013).), and improved hydrazide chemical method (document 4. Zeng, Y., Ramya, T.N., Dirksen, A., Dawson, P.E. & Paulson, J.C. High-efficiency labeling of sialylated glycoproteins on living cells. Nature methods 6, 207-209, doi: 10.1038/nmeth.1305 (2009). Literature 5 .Nilsson,J.et al.Enrichment of glycopeptides for glycan structure and attachment site identification. Nature methods 6, 809-811, doi: 10.1038/nmeth.1392 (2009). Document 6. Tian, Y., Esteva, F.J., Song, J. & Zhang, H. Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry. Mol. Cell. Proteomics, doi: 10.1074/mcp. M111.011403 (2012).). The improved hydrazide chemistry method refers to the selective oxidation of sialylated glycoproteins or glycopeptides with a low concentration of sodium periodate solution at low temperature and in a short period of time to achieve their enrichment and analysis. These reported methods directly compare the difference in sialylation at the same glycosylation site between disease samples and normal samples, but there is no study on the occupancy of sialylated sugar chains on glycoproteins in samples of the same state.
唾液酸化糖链的占有率可定义为一个蛋白质上同一个糖基化位点上唾液酸化糖链占所有糖链的摩尔比。研究表明,糖链的末端唾液酸可以被低浓度的高碘酸钠溶液选择性氧化,而所有种类的糖链可以被高浓度的高碘酸钠溶液氧化。本发明首次利用不同浓度的高碘酸钠溶液差异氧化同一个生物样品中的糖蛋白,发展了一种蛋白层次上高通量定量糖蛋白上N-连唾液酸化糖链占有率的方法。 The occupancy ratio of sialylated sugar chains can be defined as the molar ratio of sialylated sugar chains to all sugar chains at the same glycosylation site on a protein. Studies have shown that the terminal sialic acid of sugar chains can be selectively oxidized by low-concentration sodium periodate solution, while all kinds of sugar chains can be oxidized by high-concentration sodium periodate solution. The present invention uses different concentrations of sodium periodate solutions to differentially oxidize glycoproteins in the same biological sample for the first time, and develops a method for quantifying the occupancy of N-linked sialylated sugar chains on glycoproteins at the protein level with high throughput.
发明内容 Contents of the invention
本发明的目的在于提供一种可以简便、准确、高通量定量复杂生物样品中糖蛋白上N-连唾液酸化糖链占有率的方法。首先取同一种状态下含糖蛋白的生物样品等量两份,然后用高碘酸钠溶液对其分别处理以进行差异氧化,之后利用蛋白层次上的酰肼化学法富集差异氧化后的样品中的糖蛋白,再利用不同稳定同位素差异标记酰肼微球上的糖肽,然后用肽糖苷酶PNGase F处理,最后对混合差异标记的N-糖肽进行质谱分析,以定量N-连唾液酸化糖链的占有率。 The purpose of the present invention is to provide a simple, accurate and high-throughput method for quantifying the occupancy of N-linked sialylated sugar chains on glycoproteins in complex biological samples. First, take two equal biological samples containing glycoproteins in the same state, and then treat them separately with sodium periodate solution for differential oxidation, and then use the hydrazide chemical method on the protein level to enrich the differentially oxidized samples Then use different stable isotopes to differentially label the glycopeptides on the hydrazide microspheres, then treat them with peptide glycosidase PNGase F, and finally perform mass spectrometry analysis on the mixed differentially labeled N-glycopeptides to quantify N-linked saliva Occupancy of acidified sugar chains.
具体包含以下步骤, Specifically include the following steps,
1)取同一种状态下含糖蛋白的生物样品等量两份,分别溶解在含6-8M Urea和50-100mM NH4HCO3的缓冲溶液中,沸水加热失活5-10min,用蛋白除盐柱除去其中的小分子,全蛋白在缓冲溶液中的浓度为2-10mg/mL; 1) Take two equal parts of biological samples containing glycoproteins in the same state, dissolve them in a buffer solution containing 6-8M Urea and 50-100mM NH 4 HCO 3 , heat inactivation in boiling water for 5-10min, deactivate with protein The small molecules in the salt column are removed, and the concentration of the whole protein in the buffer solution is 2-10mg/mL;
2)步骤1)结束后得到的两份经过处理的样品,一份用浓度为0.5-1mM的高碘酸钠溶液氧化,另一份用浓度为10-15mM的高碘酸钠溶液氧化,氧化之后的两个样品各以蛋白除盐柱置换为含浓度为80-100mM NaAC和130-150mM的NaCl的缓冲溶液,向两个溶液中各加入预先以此缓冲溶液洗离过2~3次的酰肼微球,室温震荡富集10-12h,酰肼微球自身所占的体积与步骤2)所置换的缓冲溶液的体积比为1:5; 2) Two parts of processed samples obtained after step 1) are completed, one is oxidized with a sodium periodate solution of 0.5-1mM with a concentration, and the other is oxidized with a sodium periodate solution of 10-15mM with a concentration, and the oxidized The following two samples were replaced with a buffer solution containing 80-100mM NaAC and 130-150mM NaCl with a protein desalting column, and each of the two solutions was added to the two solutions. Hydrazide microspheres, enriched by shaking at room temperature for 10-12h, the volume ratio of the volume occupied by the hydrazide microspheres to the buffer solution replaced in step 2) is 1:5;
3)步骤2)结束后得到的酰肼微球用浓度为50-100mM的 NH4HCO3溶液洗离2~3次以除去非糖蛋白,然后各分散在含浓度为6-8M的Urea和浓度为50-100mM的NH4HCO3的缓冲液中,用终浓度为10-20mM的DDT和浓度为20-40mM的IAA各依次处理后,再依次以80-90%ACN(ACN和H2O的体积比),50-100mM NH4HCO3溶液各洗离2~3次,最后均分散在50-100mM NH4HCO3缓冲液中,酰肼微球自身所占的体积与加入的50-100mM NH4HCO3缓冲液的体积比为1:5,再各加入胰蛋白酶酶解12-16h,加入的胰蛋白酶的用量与步骤1)所取的样品中蛋白质的质量比为1:25; 3) The hydrazide microspheres obtained after step 2) were washed with 50-100mM NH 4 HCO 3 solution for 2 to 3 times to remove non-glycoproteins, and then dispersed in 6-8M Urea and Concentration is 50-100mM NH 4 HCO 3 in the buffer solution, with the DDT that is 10-20mM final concentration and the IAA that concentration is 20-40mM each successively after treatment, then with 80-90% ACN (ACN and H 2 O volume ratio), 50-100mM NH 4 HCO 3 solution was washed away 2 to 3 times, and finally dispersed in 50-100mM NH 4 HCO 3 buffer solution, the volume occupied by the hydrazide microspheres itself and the added 50 The volume ratio of -100mM NH 4 HCO 3 buffer solution is 1:5, and then add trypsin to digest for 12-16h, the mass ratio of the amount of trypsin added to the protein in the sample taken in step 1) is 1:25 ;
4)步骤3)得到的微球各依次以1.0-1.5M NaCl溶液,80-90%ACN(ACN和H2O的体积比),50-100mM NH4HCO3溶液和水洗去非特异性吸附和非糖肽,并分别分散在200-400μL 50-100mM TEAB中,分别取8-16μL 4-8wt%CD2O/CH2O(CD2O和CH2O都是4%-8%)和0.6-1.2M NaBH3CN各依次加入到两种样品中,室温反应3-4h以实现糖肽的二甲基重/轻标记,4-8%D2O/CH2O与微球自身体积比为2:25-4:25,0.6-1.2M NaBH3CN与微球自身的体积比为2:25-4:25; 4) The microspheres obtained in step 3) are washed successively with 1.0-1.5M NaCl solution, 80-90% ACN (volume ratio of ACN and H 2 O), 50-100 mM NH 4 HCO 3 solution and water to remove non-specific adsorption and Non-glycopeptides, and dispersed in 200-400μL 50-100mM TEAB, respectively, take 8-16μL 4-8wt% CD 2 O/CH 2 O (both CD 2 O and CH 2 O are 4%-8%) and Add 0.6-1.2M NaBH 3 CN to the two samples in turn, react at room temperature for 3-4 hours to achieve dimethyl heavy/light labeling of glycopeptides, 4-8% D 2 O/CH 2 O and the volume of the microspheres The ratio is 2:25-4:25, the volume ratio of 0.6-1.2M NaBH 3 CN to the microsphere itself is 2:25-4:25;
5)在用水洗离步骤4)得到的酰肼微球2~3次后,各加入含500-1000Unites PNGase F的10-20mM NH4HCO3缓冲液震荡酶切10-12h,将二甲基标记的N-糖肽酶切下来,将对应的轻标和重标的样品以等体积混合,所得的样品以MALDI-TOF/TOF mass spectrometer或LC-MS/MS分析,以定量N-连唾液酸化糖链的占有率;其中加入的含PNGase F的缓冲溶液的体积与酰肼微球自身所占体积的比例为2:1-4:1。 5) After washing the hydrazide microspheres obtained in step 4) with water for 2 to 3 times, add 10-20 mM NH 4 HCO 3 buffer solution containing 500-1000 Unites PNGase F and shake the enzyme for 10-12 hours to digest the dimethyl The labeled N-glycopeptidase is cut off, and the corresponding light and heavy standard samples are mixed in equal volumes, and the resulting samples are analyzed by MALDI-TOF/TOF mass spectrometer or LC-MS/MS to quantify N-linked sialylation Occupancy ratio of sugar chains; the ratio of the volume of the buffer solution containing PNGase F added to the volume occupied by the hydrazide microspheres itself is 2:1-4:1.
其中,步骤1)所述的除去的小分子为尿素、碳酸氢铵以及样品中其他分子量小于7000Da的分子;步骤4)所述的100mM TEAB的pH为7.5-8.0。 Wherein, the small molecules removed in step 1) are urea, ammonium bicarbonate and other molecules with a molecular weight less than 7000Da in the sample; the pH of the 100mM TEAB in step 4) is 7.5-8.0.
本发明所述的定量糖蛋白上N-连唾液酸化糖链占有率的方法可以用于糖基化修饰的蛋白质组学分析,能同时获取相应的糖蛋白、糖肽和糖基化位点的鉴定结果,尤其可以用于人肝癌(HCC)的潜在生物标志物的筛选。 The method for quantifying the occupancy of N-linked sialylated sugar chains on glycoproteins of the present invention can be used for proteomics analysis of glycosylation modifications, and can simultaneously obtain corresponding glycoproteins, glycopeptides, and glycosylation sites. The identification result can especially be used for the screening of potential biomarkers of human liver cancer (HCC).
所述的基于酰肼化学的差异氧化和标记法用于高通量定量糖蛋白上N-连唾液酸化糖链的占有率,所用的糖蛋白富集材料为商品化的琼脂糖酰肼微球(Bio-Rad,CA,USA)。 The differential oxidation and labeling method based on hydrazide chemistry is used for high-throughput quantification of the occupancy of N-linked sialylated sugar chains on glycoproteins, and the glycoprotein enrichment material used is commercial agarose hydrazide microspheres (Bio-Rad, CA, USA).
所述的基于酰肼化学的差异氧化和标记法用于高通量定量糖蛋白上N-连唾液酸化糖链的占有率,所用的定量方法为相对定量法。即用CD2O标记0.5-1mM高碘酸钠溶液氧化后富集的糖肽,用CH2O标记10-15mM高碘酸钠溶液氧化后富集的糖肽,两者等摩尔量混合后进行质谱分析。 The differential oxidation and labeling method based on hydrazide chemistry is used for high-throughput quantification of the occupancy of N-linked sialylated sugar chains on glycoproteins, and the quantitative method used is a relative quantitative method. That is, label the glycopeptide enriched after oxidation with 0.5-1mM sodium periodate solution with CD 2 O, label the glycopeptide enriched after oxidation with 10-15mM sodium periodate solution with CH 2 O, and mix the two equimolar amounts Perform mass spectrometry.
本发明的优点: Advantages of the present invention:
本发明所述方法具有明显的优点:简便,高效,高通量。酰肼化学法富集糖肽已在糖蛋白质组学分析中广泛应用,它具有材料易得,操作简便,富集特异性高,高效等优点。本发明的实验流程是在蛋白层次上运用酰肼化学法,使得一个样品的整个操作流程可以在一个样品管中完成,大大简化了操作,节省了时间。本发明首次利用酰肼化学法中不同浓度的高碘酸钠溶液差异氧化同一个糖蛋白上的末端是唾液酸的糖链和全部类型的糖链,再利用轻重同位素标记和高分辨率的RPLC-MS/MS分析,从而实现对分析样品中N-连唾液酸糖链占有率的高效、高通量定量。 The method of the invention has obvious advantages: simplicity, high efficiency and high throughput. The hydrazide chemical method for enriching glycopeptides has been widely used in the analysis of glycoproteomics. It has the advantages of easy-to-obtain materials, easy operation, high enrichment specificity, and high efficiency. The experimental process of the present invention uses the hydrazide chemical method at the protein level, so that the entire operation process of one sample can be completed in one sample tube, which greatly simplifies the operation and saves time. For the first time, the present invention utilizes sodium periodate solutions of different concentrations in the hydrazide chemical method to differentially oxidize sugar chains and all types of sugar chains with sialic acid at the end of the same glycoprotein, and then utilizes light and heavy isotope labeling and high-resolution RPLC -MS/MS analysis, so as to achieve efficient and high-throughput quantification of the occupancy of N-linked sialic acid sugar chains in the analyzed samples.
附图说明 Description of drawings
下面结合附图及实施方式对本发明作进一步详细的说明: Below in conjunction with accompanying drawing and embodiment the present invention is described in further detail:
图1为所述基于酰肼化学的差异氧化和标记法高通量定量糖蛋白上N-连唾液酸化糖链占有率的实验流程图。 Fig. 1 is an experimental flowchart of the high-throughput quantification of the occupancy of N-linked sialylated sugar chains on glycoproteins by the differential oxidation and labeling method based on hydrazide chemistry.
图2A为所述基于酰肼化学的差异氧化和标记法用于特异性富集、定量标准糖蛋白—人血清转铁蛋白(Transferrin from human blood plasma,HT)上N-连唾液酸化糖链占有率的MALDT-TOF质谱图;图2B为所述基于酰肼化学的差异氧化和标记法用于特异性富集、定量标准糖蛋白—部分去唾液酸化的人血清转铁蛋白(Asialo transferrin from human blood plasma,AHT)上N-连唾液酸化糖链占有率的MALDT-TOF质谱图。 Figure 2A shows that the differential oxidation and labeling method based on hydrazide chemistry was used to specifically enrich and quantify the occupancy of N-linked sialylated sugar chains on human serum transferrin (Transferrin from human blood plasma, HT). The MALDT-TOF mass spectrum of the ratio; Figure 2B is the differential oxidation and labeling method based on hydrazide chemistry for specific enrichment and quantification of standard glycoproteins—partially desialylated human serum transferrin (Asialo transferrin from human MALDT-TOF mass spectrum of N-linked sialylated sugar chain occupancy on blood plasma (AHT).
图3A为所述基于酰肼化学的差异氧化和标记法定量到的人肝癌组织(HCC)和正常肝组织(Normal)中糖蛋白上N-连唾液酸化糖链占有率的Log2值的分布图;图3B为所述基于酰肼化学的差异氧化和标记法定量到的人肝癌组织(HCC)和正常肝组织(Normal)中同时存在的糖蛋白上N-连糖基化位点数图。 Figure 3A is the distribution of the Log 2 value of the occupancy of N-linked sialylated sugar chains on glycoproteins quantified by the differential oxidation and labeling method based on hydrazide chemistry in human liver cancer tissue (HCC) and normal liver tissue (Normal) Figures; Figure 3B is a graph of the number of N-linked glycosylation sites on glycoproteins that are simultaneously present in human liver cancer tissue (HCC) and normal liver tissue (Normal) quantified by the differential oxidation and labeling method based on hydrazide chemistry.
图4为所述基于酰肼化学的差异氧化和标记法定量到的人肝癌组织(HCC)和正常肝组织(Normal)中同时存在的糖蛋白上N-连唾液酸化糖链的占有率的比值的Log2值的分布图。 Figure 4 is the ratio of the occupancy ratio of N-linked sialylated sugar chains on glycoproteins that are simultaneously present in human liver cancer tissue (HCC) and normal liver tissue (Normal) quantified by the differential oxidation and labeling method based on hydrazide chemistry Distribution plot of Log 2 values.
具体实施方式 detailed description
材料与试剂: Materials and Reagents:
人血清转铁蛋白(Transferrin from human blood plasma,HT),高碘酸钠(sodium periodate),二硫苏糖醇(1,4-dithiothreitol,DTT),碘代乙酰胺(iodacetamide,IAA),胰蛋白酶(trypsin),2,5-二羟基苯甲酸(2,5-dihydroxyl benzoic acid,DHB)和三乙基碳酸氢铵(triethylammonium bicarbonate buffer,TEAB)缓冲液均购自Sigma公司(IL,U.S.A.)。蛋白除盐柱(Zeba Spin desalting columns)购自Thermo Scientific公司(IL,U.S.A.)。琼脂糖酰肼微球(hydrazide sepharose resin)购自Bio-Rad公司(CA,U.S.A.)。肽糖苷酶 (Peptide-N-glycosidase F,PNGase F)和去唾液酸酶(Neuraminidase)购自New England Biolabs公司(MA,U.S.A.)。实验用水经购自Millipore公司(MA,U.S.A.)的Milli-Q水处理系统纯化。其他试剂均为分析纯或更高纯度。 Human serum transferrin (Transferrin from human blood plasma, HT), sodium periodate (sodium periodate), dithiothreitol (1,4-dithiothreitol, DTT), iodoacetamide (iodacetamide, IAA), pancreatic Protease (trypsin), 2,5-dihydroxyl benzoic acid (2,5-dihydroxyl benzoic acid, DHB) and triethylammonium bicarbonate (triethylammonium bicarbonate buffer, TEAB) buffer were purchased from Sigma (IL, U.S.A.) . Protein desalting columns (Zeba Spin desalting columns) were purchased from Thermo Scientific (IL, U.S.A.). Sepharose hydrazide microspheres (hydrazide sepharose resin) were purchased from Bio-Rad (CA, U.S.A.). Peptide-N-glycosidase F, PNGase F and neuraminidase were purchased from New England Biolabs (MA, U.S.A.). Experimental water was purified by Milli-Q water treatment system purchased from Millipore Corporation (MA, U.S.A.). All other reagents were of analytical grade or higher.
实施例1定量标准糖蛋白上N-连唾液酸化糖链的占有率 Example 1 Occupancy of N-linked sialylated sugar chains on quantitative standard glycoproteins
人血清转铁蛋白(HT)是一种简单易得的糖蛋白,它的两个N-糖基化位点上的糖链末端均是唾液酸(文献7.Satomi,Y.,Shimonishi,Y.,Hase,T.&Takao,T.Site-specific carbohydrate profiling of human transferrin by nano-flow liquid chromatography/electrospray ionization mass spectrometry.Rapid communications in mass spectrometry:RCM18,2983-2988,doi:10.1002/rcm.1718(2004).)。末端唾液酸可以被去唾液酸酶部分去除,得到去唾液酸化的转铁蛋白(AHT)(文献6)。利用本发明所述的方法定量这两种标准糖蛋白上N-连唾液酸化糖链占有率的实验流程如图1所示。 Human serum transferrin (HT) is a simple and easy-to-obtain glycoprotein, and the sugar chain ends on its two N-glycosylation sites are all sialic acid (document 7.Satomi, Y., Shimonishi, Y .,Hase,T.&Takao,T.Site-specific carbohydrate profiling of human transferrin by nano-flow liquid chromatography/electrospray ionization mass spectrometry.Rapid communications in mass spectrometry:RCM18,2983-2988,doi:10.1002/rcm.1718( 2004).). The terminal sialic acid can be partially removed by desialidase to obtain desialylated transferrin (AHT) (Reference 6). The experimental flow for quantifying the occupancy of N-linked sialylated sugar chains on the two standard glycoproteins by using the method of the present invention is shown in FIG. 1 .
1.两种标准糖蛋白各取两份1mg,分别溶解在100μL含8M Urea和100mM NH4HCO3的缓冲液中(pH 8.2),在沸水中加热失活10min后,用蛋白除盐柱除去小分子。接下来的实验是对四个样品分别、平行进行操作。 1. Take two 1mg portions of each of the two standard glycoproteins, dissolve them in 100μL buffer containing 8M Urea and 100mM NH 4 HCO 3 (pH 8.2), inactivate them by heating in boiling water for 10min, and remove them with a protein desalting column Small molecule. The next experiment is to operate the four samples separately and in parallel.
2.HT和AHT各一份用1mM高碘酸钠氧化,另一份用10mM高碘酸钠氧化。四个样品各以蛋白除盐柱置换为含100mM NaAc和150mM NaCl的缓冲溶液(pH 5.5)后,各加入预先以此缓冲溶液洗离过两次的100μL酰肼微球(微球自身所占体积),室温震荡富集过夜。 2. One part of HT and AHT was oxidized with 1 mM sodium periodate, and the other part was oxidized with 10 mM sodium periodate. After each of the four samples was replaced with a buffer solution (pH 5.5) containing 100mM NaAc and 150mM NaCl with a protein desalting column, each of them was added with 100 μL of hydrazide microspheres (the microspheres themselves occupied volume), enriched overnight by shaking at room temperature.
3.酰肼微球用500μL 100mM NH4HCO3(pH 8.2)洗离三次以除去非糖蛋白,然后各分散在500μL含8M Urea和100mM NH4HCO3的缓冲液中(pH 8.2)。用终浓度为10mM DTT和20mM IAA处理后,再依次以500μL 80%ACN,100mM NH4HCO3各洗离三次,最后均分散在500μL 100mM NH4HCO3中,各加入40μg胰蛋白酶酶解过夜。 3. The hydrazide microspheres were washed three times with 500 μL of 100 mM NH 4 HCO 3 (pH 8.2) to remove non-glycoproteins, and then dispersed in 500 μL of buffer containing 8M Urea and 100 mM NH 4 HCO 3 (pH 8.2). After treatment with a final concentration of 10mM DTT and 20mM IAA, wash with 500μL 80% ACN and 100mM NH 4 HCO 3 for three times, and finally disperse them in 500μL 100mM NH 4 HCO 3 , add 40μg trypsin to digest overnight .
4.依次以500μL 1.5M NaCl,80%ACN,100mM NH4HCO3溶液和水洗去非特异性吸附和非糖肽,并分别分散在400μL 100mM TEAB(pH 8.0)中。分别取16μL 4%CD2O/CH2O和16μL 0.6M NaBH3CN依次加入1mM/10mM高碘酸钠氧化的样品中,室温反应3h以实现二甲基重/轻标记。 4. Wash non-specific adsorption and non-glycopeptides with 500 μL 1.5M NaCl, 80% ACN, 100 mM NH 4 HCO 3 solution and water in sequence, and disperse in 400 μL 100 mM TEAB (pH 8.0) respectively. 16 μL of 4% CD 2 O/CH 2 O and 16 μL of 0.6M NaBH 3 CN were respectively added to the sample oxidized by 1 mM/10 mM sodium periodate in sequence, and reacted at room temperature for 3 h to achieve dimethyl heavy/light labeling.
5.在用水洗离酰肼微球三次后,各加入200μL含500Unites PNGase F的10mM NH4HCO3缓冲液震荡酶切过夜,将二甲基标记的N-糖肽酶切下来。将HT和AHT对应的轻标和重标的样品各自以等体积混合,所得的两个样品,即HT-10mM_L-and-1mM_H和 AHT-10mM_L-and-1mM_H。分别以MALDI-TOF/TOF mass spectrometer分析。 5. After washing the hydrazide microspheres with water three times, add 200 μL of 10 mM NH 4 HCO 3 buffer solution containing 500 Unites PNGase F and shake overnight to digest the dimethyl-labeled N-glycopeptidase. Mix the light standard and heavy standard samples corresponding to HT and AHT in equal volumes, and the resulting two samples are HT-10mM_L-and-1mM_H and AHT-10mM_L-and-1mM_H. Analyzed by MALDI-TOF/TOF mass spectrometer respectively.
分析结果: Analysis results:
如图2A和2B所示,HT中轻重标记的糖肽以相近峰强度被检出,而AHT中两个N-连糖基化位点对应的重标标记的糖肽的峰强度明显低于轻标标记的糖肽的峰强度。图2A说明HT的两个糖基化位点上N-连唾液酸化糖链的占有率接近100%,这与文献报道的一致(文献7)。图2B说明N-连唾液酸化糖链去唾液酸后,其对应的糖肽的峰强度也随之降低。因此,两种糖蛋白的对应的糖基化位点上N-连唾液酸化糖链的占有率可以由重标糖肽的峰强度比上轻标糖肽的峰强度计算得到(H/L),如表1所示。显然,本发明设计的方法可以简便、高效的定量糖蛋白上N-连唾液酸化糖链的占有率。 As shown in Figures 2A and 2B, the lightly and heavily labeled glycopeptides in HT were detected with similar peak intensities, while the peak intensities of the heavily labeled glycopeptides corresponding to the two N-linked glycosylation sites in AHT were significantly lower than Peak intensities of lightly labeled glycopeptides. Figure 2A shows that the occupancy rate of N-linked sialylated sugar chains on the two glycosylation sites of HT is close to 100%, which is consistent with that reported in the literature (Document 7). Figure 2B shows that after the N-linked sialylated sugar chain is desialic acid, the peak intensity of the corresponding glycopeptide is also reduced. Therefore, the occupancy of N-linked sialylated sugar chains on the corresponding glycosylation sites of the two glycoproteins can be calculated from the peak intensity of the heavy-labeled glycopeptide compared to the peak intensity of the upper light-labeled glycopeptide (H/L) ,As shown in Table 1. Obviously, the method designed in the present invention can simply and efficiently quantify the occupancy of N-linked sialylated sugar chains on glycoproteins.
表1.所述基于酰肼化学的差异氧化和标记法定量到的HT和AHT上N-连唾液酸化糖链的占有率 Table 1. Occupancy of N-linked sialylated sugar chains on HT and AHT quantified by the differential oxidation and labeling method based on hydrazide chemistry
实施例2 Example 2
我们将此方法用于分别定量肝癌病人的肝组织和正常人的肝组织中糖蛋白上N-连唾液酸化糖链的占有率,并比较两种状态下糖蛋白上N-连唾液酸化糖链的占有率的变化,从而发现人肝癌中潜在的生物标志物。 We used this method to quantify the occupancy of N-linked sialylated sugar chains on glycoproteins in the liver tissues of liver cancer patients and normal people, and compared the N-linked sialylated sugar chains on glycoproteins in the two states Changes in the occupancy rate of HCC, thereby discovering potential biomarkers in human liver cancer.
本实验所用的人肝组织样品由大连医科大学附属第二医院(大连,中国)提供,是肝细胞癌(HCC)肝脏外周(≥2cm)的非癌症组织。正常组织部分(Normal)做过病理切片,样品的取得和使用完全合法,并符合该院伦理委员会的相关规定。从肝组织中提取的蛋白质溶液的处理流程与标准蛋白一样,如图1所示。最终,以在两次及两次以上质谱重复中均定量到为标准,从肝癌组织中共定量到334个糖蛋白上496个位点特异性的N-连唾液酸化糖链的占有率;从正常肝组织中共定量到394个糖蛋白上632个位点特异性的N-连唾液酸化糖链的占有率。两种样品的N-连唾液酸化糖链占有率的Log2值 的分布如图3A所示。可以看出,正常肝组织中N-连唾液酸化糖链的占有率在总体上较癌组织中更高。可以推测,两种样品中某些特定的糖蛋白上的N-连唾液酸化糖链的占有率发生了显著变化。如图3B所示,有284个N-连糖基化位点同时存在于两个样品中。我们计算了这284个位点上N-连唾液酸化糖链占有率的比值,图4给出了这个比值的Log2值的分布。发现两个样品中共同的76个N-糖基化位点上的唾液酸化糖链的占有率有显著差异,其中37个糖蛋白上的40个N-连唾液酸化糖链的占有率显著下调,31个糖蛋白上的36个N-连唾液酸化糖链的占有率显著上调。这些糖蛋白可以用来进一步筛选人肝癌的标志物。 The human liver tissue samples used in this experiment were provided by the Second Affiliated Hospital of Dalian Medical University (Dalian, China), which are non-cancerous tissues around the liver (≥ 2 cm) of hepatocellular carcinoma (HCC). The normal tissue part (Normal) had been pathologically sliced, and the acquisition and use of the samples were completely legal and in compliance with the relevant regulations of the ethics committee of the hospital. The processing procedure of the protein solution extracted from the liver tissue is the same as that of the standard protein, as shown in Figure 1. Finally, the occupancy rate of 496 site-specific N-linked sialylated sugar chains on 334 glycoproteins was quantified from liver cancer tissues based on the quantification in two or more mass spectrometry repetitions; The occupancy of 632 site-specific N-linked sialylated sugar chains on 394 glycoproteins were quantified in liver tissue. The distribution of the Log 2 values of the occupancy of N-linked sialylated sugar chains of the two samples is shown in Fig. 3A. It can be seen that the occupancy rate of N-linked sialylated sugar chains in normal liver tissue is generally higher than that in cancer tissue. It can be speculated that the occupancy of N-linked sialylated sugar chains on some specific glycoproteins changed significantly in the two samples. As shown in Figure 3B, 284 N-linked glycosylation sites were present in both samples. We calculated the ratio of the occupancy of N-linked sialylated sugar chains on these 284 sites, and Figure 4 shows the distribution of the Log 2 value of this ratio. Significant differences were found in the occupancy of sialylated sugar chains on 76 common N-glycosylation sites in the two samples, among which the occupancy of 40 N-linked sialylated sugar chains on 37 glycoproteins was significantly down-regulated , the occupancy of 36 N-linked sialylated sugar chains on 31 glycoproteins was significantly up-regulated. These glycoproteins can be used to further screen for markers of human liver cancer.
结论 in conclusion
显然,本发明发展的方法可以简便、高效、高通量的定量复杂生物样品中糖蛋白上N-连唾液酸化糖链的占有率,为筛选疾病标志物提供了一种不受蛋白质丰度影响的新思路,在疾病标志物的研究中将起到重要作用。 Apparently, the method developed by the present invention can quantify the occupancy of N-linked sialylated sugar chains on glycoproteins in complex biological samples in a simple, efficient and high-throughput manner, providing a method for screening disease markers that is not affected by protein abundance. The new idea will play an important role in the study of disease markers.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510060851.XA CN105987945A (en) | 2015-02-05 | 2015-02-05 | Quantitative method for occupancy of N-bond sialylated sugar chains on glycoprotein and application of quantitative method in hepatoma marker screening |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510060851.XA CN105987945A (en) | 2015-02-05 | 2015-02-05 | Quantitative method for occupancy of N-bond sialylated sugar chains on glycoprotein and application of quantitative method in hepatoma marker screening |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105987945A true CN105987945A (en) | 2016-10-05 |
Family
ID=57037725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510060851.XA Pending CN105987945A (en) | 2015-02-05 | 2015-02-05 | Quantitative method for occupancy of N-bond sialylated sugar chains on glycoprotein and application of quantitative method in hepatoma marker screening |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105987945A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107765017A (en) * | 2017-10-09 | 2018-03-06 | 广东医科大学 | Markers for breast cancer |
| CN109142506A (en) * | 2017-06-18 | 2019-01-04 | 复旦大学 | A method of based on mass spectrographic N- sugar chain relative quantitation |
| CN109959699A (en) * | 2017-12-14 | 2019-07-02 | 中国科学院大连化学物理研究所 | A mass spectrometry method for the detection of intact glycosylated peptides based on pseudo-multilevel spectroscopy |
| CN110261500A (en) * | 2019-05-30 | 2019-09-20 | 同济大学 | One kind being based on mass spectrographic complete N- glycopeptide relative quantitation method |
| CN110702916A (en) * | 2019-04-15 | 2020-01-17 | 四川大学华西医院 | Quantitative analysis method for integrating proteome and glycoprotein |
| CN111157736A (en) * | 2018-11-08 | 2020-05-15 | 中国科学院大连化学物理研究所 | Human serum O glycosylation identification method based on chemoenzymatic |
| CN114032282A (en) * | 2021-09-15 | 2022-02-11 | 陈翠英 | Prostate cancer detection reagent and application thereof in prostate cancer detection |
| CN114032281A (en) * | 2021-09-15 | 2022-02-11 | 陈翠英 | Hepatitis C liver cancer detection reagent and application thereof in hepatitis C liver cancer detection |
| CN114839280A (en) * | 2022-03-23 | 2022-08-02 | 苏州大学 | A method based on solid-phase fucose glycoprotein enrichment and fucose glycosylation enzyme cleavage analysis |
| CN115201347A (en) * | 2021-04-13 | 2022-10-18 | 中轻食品检验认证有限公司 | Method for detecting fermentation-derived sialic acid in food |
| CN120174094A (en) * | 2025-03-26 | 2025-06-20 | 华东理工大学 | A probe group and a method for analyzing sialic acid of specific glycoprotein on the surface of exosomes by combining the probe group and the 3D printed microfluidic chip |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0881494A1 (en) * | 1997-04-29 | 1998-12-02 | Roche Diagnostics GmbH | Method of simultaneous determination of proteins and their derivatives |
| GB2387265A (en) * | 2001-11-13 | 2003-10-08 | Bruker Daltonik Gmbh | Mass determination for biopolymers |
| CN1520462A (en) * | 2001-06-28 | 2004-08-11 | Ī��ʲ��ѧ | Method for detecting kidney disease by protein profiling |
| CN101104594A (en) * | 2002-12-26 | 2008-01-16 | 盐野义制药株式会社 | Method of purifying/concentrating sugar chain with sugar chain-trapping molecule and method of analyzing sugar chain structure |
-
2015
- 2015-02-05 CN CN201510060851.XA patent/CN105987945A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0881494A1 (en) * | 1997-04-29 | 1998-12-02 | Roche Diagnostics GmbH | Method of simultaneous determination of proteins and their derivatives |
| CN1520462A (en) * | 2001-06-28 | 2004-08-11 | Ī��ʲ��ѧ | Method for detecting kidney disease by protein profiling |
| GB2387265A (en) * | 2001-11-13 | 2003-10-08 | Bruker Daltonik Gmbh | Mass determination for biopolymers |
| CN101104594A (en) * | 2002-12-26 | 2008-01-16 | 盐野义制药株式会社 | Method of purifying/concentrating sugar chain with sugar chain-trapping molecule and method of analyzing sugar chain structure |
Non-Patent Citations (1)
| Title |
|---|
| ZHANG ZHAN,ET AL: "High-Throughput Determination of the Site-Specific N‑Sialoglycan Occupancy Rates by Differential Oxidation of Glycoproteins Followed with Quantitative Glycoproteomics Analysis", 《ANALYTICAL CHEMISTRY》 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109142506B (en) * | 2017-06-18 | 2022-03-18 | 复旦大学 | Method for relatively quantifying N-sugar chain based on mass spectrum |
| CN109142506A (en) * | 2017-06-18 | 2019-01-04 | 复旦大学 | A method of based on mass spectrographic N- sugar chain relative quantitation |
| CN107765017B (en) * | 2017-10-09 | 2020-01-10 | 广东医科大学 | Markers for breast cancer |
| CN107765017A (en) * | 2017-10-09 | 2018-03-06 | 广东医科大学 | Markers for breast cancer |
| CN109959699A (en) * | 2017-12-14 | 2019-07-02 | 中国科学院大连化学物理研究所 | A mass spectrometry method for the detection of intact glycosylated peptides based on pseudo-multilevel spectroscopy |
| CN111157736A (en) * | 2018-11-08 | 2020-05-15 | 中国科学院大连化学物理研究所 | Human serum O glycosylation identification method based on chemoenzymatic |
| CN110702916A (en) * | 2019-04-15 | 2020-01-17 | 四川大学华西医院 | Quantitative analysis method for integrating proteome and glycoprotein |
| CN110702916B (en) * | 2019-04-15 | 2022-06-21 | 四川大学华西医院 | A Quantitative Analysis Method Integrating Proteome and Glycoproteome |
| CN110261500A (en) * | 2019-05-30 | 2019-09-20 | 同济大学 | One kind being based on mass spectrographic complete N- glycopeptide relative quantitation method |
| CN115201347A (en) * | 2021-04-13 | 2022-10-18 | 中轻食品检验认证有限公司 | Method for detecting fermentation-derived sialic acid in food |
| CN114032281A (en) * | 2021-09-15 | 2022-02-11 | 陈翠英 | Hepatitis C liver cancer detection reagent and application thereof in hepatitis C liver cancer detection |
| CN114032282A (en) * | 2021-09-15 | 2022-02-11 | 陈翠英 | Prostate cancer detection reagent and application thereof in prostate cancer detection |
| WO2023040910A1 (en) * | 2021-09-15 | 2023-03-23 | 江苏先思达生物科技有限公司 | Hepatitis c and hepatic cancer detection reagent, and application thereof in hepatitis c and hepatic cancer detection |
| CN114839280A (en) * | 2022-03-23 | 2022-08-02 | 苏州大学 | A method based on solid-phase fucose glycoprotein enrichment and fucose glycosylation enzyme cleavage analysis |
| WO2023178911A1 (en) * | 2022-03-23 | 2023-09-28 | 苏州大学 | Enzyme digestion analysis method based on solid-phase fucose glycoprotein enrichment and fucosylation |
| CN120174094A (en) * | 2025-03-26 | 2025-06-20 | 华东理工大学 | A probe group and a method for analyzing sialic acid of specific glycoprotein on the surface of exosomes by combining the probe group and the 3D printed microfluidic chip |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105987945A (en) | Quantitative method for occupancy of N-bond sialylated sugar chains on glycoprotein and application of quantitative method in hepatoma marker screening | |
| Haselberg et al. | Capillary electrophoresis–mass spectrometry for the analysis of intact proteins 2007–2010 | |
| Zhang et al. | Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry | |
| Sun et al. | Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides | |
| Chen et al. | Proteomic profiling of pancreatic cancer for biomarker discovery | |
| Mayr et al. | Absolute Myoglobin Quantitation in Serum by Combining Two-Dimensional Liquid Chromatography− Electrospray Ionization Mass Spectrometry and Novel Data Analysis Algorithms | |
| Huang et al. | A peptide N-terminal protection strategy for comprehensive glycoproteome analysis using hydrazide chemistry based method | |
| CN109959699B (en) | A mass spectrometry method for the detection of intact glycosylated peptides based on pseudo-multilevel spectroscopy | |
| Shen et al. | Isolation and isotope labeling of cysteine-and methionine-containing tryptic peptides: application to the study of cell surface proteolysis | |
| CN105771942A (en) | Magnetic nano material and preparation and application thereof | |
| CN112996580B (en) | Tandem paired column chemistry for high throughput proteomic exosome analysis | |
| Yang et al. | Solid‐phase glycan isolation for glycomics analysis | |
| Zhu et al. | Populations of metal-glycan structures influence MS fragmentation patterns | |
| Yang et al. | Chemoenzymatic method for glycomics: isolation, identification, and quantitation | |
| Nice | The separation sciences, the front end to proteomics: An historical perspective | |
| Cai et al. | Collagen derived species-specific peptides for distinguishing donkey-hide gelatin (Asini Corii Colla) | |
| Mao et al. | Comprehensive plasma N-glycoproteome profiling based on EThcD-sceHCD-MS/MS | |
| Chiou et al. | Clinical proteomics: current status, challenges, and future perspectives | |
| Sechi et al. | A method to define the carboxyl terminal of proteins | |
| Li et al. | Purification, identification and profiling of serum amyloid A proteins from sera of advanced-stage cancer patients | |
| CN108948176B (en) | Osteopontin characteristic peptide and application thereof | |
| Issaq et al. | Electrophoresis and liquid chromatography/tandem mass spectrometry in disease biomarker discovery | |
| Šimunović et al. | High‐throughput immunoaffinity enrichment and N‐glycan analysis of human plasma haptoglobin | |
| Alonso-García et al. | An inductively coupled plasma-mass spectrometry (ICP-MS) linked immunoassay by means of iodinated antibodies for transferrin quantitative analysis in breast cancer cell lines | |
| JP2013076629A (en) | METHOD FOR DISCRIMINATING α2,6-SIALO-SUGAR CHAIN FROM α2,3-SIALO-SUGAR CHAIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161005 |
|
| WD01 | Invention patent application deemed withdrawn after publication |